Also, key subtype differences in immunomodulatory and matrix-modifying protein release identified in our previous experiments could be captured in serum, such as high Loxl1 and Csf1 secretion by mesenchymal cancer cells, providing direct evidence for potential long-range effects (Fig. 6g). This evidence concerns the gene LOXL1 and cancer.